Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2
In response to the recent pandemic, vaccines have been developed for large-scale immunization. Despite safety and efficacy verified by health authorities, Guillain-Barre syndrome (GBS) remains a risk of unexpected adverse reactions. Since COVID-19-related GBS cases have largely been reported in Euro...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-09-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1922061 |
| _version_ | 1797674502468927488 |
|---|---|
| author | Char Leung |
| author_facet | Char Leung |
| author_sort | Char Leung |
| collection | DOAJ |
| description | In response to the recent pandemic, vaccines have been developed for large-scale immunization. Despite safety and efficacy verified by health authorities, Guillain-Barre syndrome (GBS) remains a risk of unexpected adverse reactions. Since COVID-19-related GBS cases have largely been reported in Europe, vaccines involving viral genetic materials can potentially trigger GBS, as demonstrated in clinical trials in the Americas. Therefore, medical professionals should be aware of GBS as a potential adverse reaction in SARS-CoV-2 vaccination. Consultation with a neurologist may be needed. Nevertheless, this is not to say that the use of vaccines against SARS-CoV-2 should be suspended and that the association between GBS and the vaccine is confirmed or excluded. The benefits of vaccine still outweigh potential adverse effects. |
| first_indexed | 2024-03-11T22:00:56Z |
| format | Article |
| id | doaj.art-b8ab3142600243e39309d62efe61fd5a |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:00:56Z |
| publishDate | 2021-09-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-b8ab3142600243e39309d62efe61fd5a2023-09-25T11:22:21ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-09-011792957295810.1080/21645515.2021.19220611922061Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2Char Leung0Deakin UniversityIn response to the recent pandemic, vaccines have been developed for large-scale immunization. Despite safety and efficacy verified by health authorities, Guillain-Barre syndrome (GBS) remains a risk of unexpected adverse reactions. Since COVID-19-related GBS cases have largely been reported in Europe, vaccines involving viral genetic materials can potentially trigger GBS, as demonstrated in clinical trials in the Americas. Therefore, medical professionals should be aware of GBS as a potential adverse reaction in SARS-CoV-2 vaccination. Consultation with a neurologist may be needed. Nevertheless, this is not to say that the use of vaccines against SARS-CoV-2 should be suspended and that the association between GBS and the vaccine is confirmed or excluded. The benefits of vaccine still outweigh potential adverse effects.http://dx.doi.org/10.1080/21645515.2021.1922061covid-19sars-cov-2guillain-barre syndromevaccine |
| spellingShingle | Char Leung Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2 Human Vaccines & Immunotherapeutics covid-19 sars-cov-2 guillain-barre syndrome vaccine |
| title | Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2 |
| title_full | Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2 |
| title_fullStr | Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2 |
| title_full_unstemmed | Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2 |
| title_short | Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2 |
| title_sort | guillain barre syndrome should be monitored upon mass vaccination against sars cov 2 |
| topic | covid-19 sars-cov-2 guillain-barre syndrome vaccine |
| url | http://dx.doi.org/10.1080/21645515.2021.1922061 |
| work_keys_str_mv | AT charleung guillainbarresyndromeshouldbemonitoreduponmassvaccinationagainstsarscov2 |